Sharma, A. ., Subudhi, S. ., Blando, J. ., Scutti, J. ., Vence, L. ., Wargo, J. ., … Sharma, P. . (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)

Goswami, S. ., Apostolou, I. ., Zhang, J. ., Skepner, J. ., Anandhan, S. ., Zhang, X. ., … Sharma, P. . (2018). Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI99760 (Original work published 2018)

Gao, J. ., Ward, J. ., Pettaway, C. ., Shi, L. ., Subudhi, S. ., Vence, L. ., … Sharma, P. . (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308